Drugs / Inactivated Influenza H1N1 vaccine
Inactivated Influenza H1N1 vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00992433 | Nov 2009 → Nov 2010 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00964951 | ? → Nov 2010 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated influenza H1N1 vaccine | “Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without...” NCT00964951 ↗ |
| Known as | 2009 H1N1 vaccine | “receive 2 doses of 15 μg or 30 μg HA 2009 H1N1 vaccine 21 days apart.” PMID 22275399 ↗ Jan 2012 |
| Known as | Influenza A (H1N1) 2009 monovalent vaccine | “Two doses inactivated, licensed, Influenza A (H1N1) 2009 monovalent vaccine; 15 or 30 micrograms (mcg) per dose; slightly opalescent suspension in phosphate buffered saline.” NCT00992433 ↗ |
| Modality | Vaccine | “inactivated influenza H1N1 virus vaccine” NCT00964951 ↗ |
| Route | Intramuscular | “delivered intramuscularly (IM)” NCT00964951 ↗ |